13F Pro13F Pro

Birchview Capital, LP

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1618205
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare61.3%$131.2M
  • Technology32.3%$69.0M
  • Energy3.5%$7.5M
  • Other2.4%$5.0M
  • Materials0.5%$1.1M

AUM History

13fpro.ai/research/fund/birchview-capital-lp-1618205

Conviction and streaks

Concentrating · top 10 = 59.9%

From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.

KLAC$KLACConviction hold25.2% weight · held 5 quartersBMY$BMYConviction hold8.0% weight · held 10 quartersNTLA$NTLAConviction hold3.2% weight · held 5 quartersSLDB$SLDBConviction hold3.1% weight · held 6 quartersBDSX$BDSXConviction hold3.0% weight · held 10 quartersUTHR$UTHRAccumulating+50% shares · 2 quarters runningZBIO$ZBIOAccumulating+467% shares · 2 quarters runningQDEL$QDELAccumulating+23% shares · 2 quarters runningTVTX$TVTXTrimming-80% shares · 6 quarters runningDCGO$DCGOTrimming-95% shares · 3 quarters runningLRCX$LRCXTrimming-13% shares · 2 quarters runningSTOK$STOKTrimming-32% shares · 2 quarters runningOLMA$OLMATrimming-26% shares · 2 quarters running

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/birchview-capital-lp-1618205

Birchview Capital, LP 13F holdings — Q2 2026

$213.8M portfolio (+21.7% QoQ) · 72 holdings · Q2 2026 13F · top 10 are 60% of the stock portfolio

All holdings — Birchview Capital, LP (Q2 2026)

72 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
NBIX$NBIXNEUROCRINE BIOSCIENCES INC$4.6M—
— PROTHENA CORP PLC - SHS$4.4M—
ACAD$ACADACADIA PHARMACEUTICALS INC$4.3M—
PTGX$PTGXProtagonist Therapeutics, Inc$4.3M+0.1%
CMPX$CMPXCompass Therapeutics, Inc.$3.7M+14%
RLMD$RLMDRELMADA THERAPEUTICS, INC.$2.8M-0.3%
ALKS$ALKSAlkermes plc.$2.6M—
HALO$HALOHALOZYME THERAPEUTICS, INC.$2.6M+229%
CLDX$CLDXCelldex Therapeutics, Inc.$2.6M-0.3%
CYTK$CYTKCYTOKINETICS INC$2.6M—
OLMA$OLMAOlema Pharmaceuticals, Inc.$2.5M-9%
VERA$VERAVera Therapeutics, Inc.$2.5M+31%
UTHR$UTHRUNITED THERAPEUTICS Corp$2.4M+0.1%
ZBIO$ZBIOZenas BioPharma, Inc.$2.4M+34%
QURE$QUREuniQure N.V.$2.3M-50%

What changed in Q2 2026

Against the previous quarter's 13F: 14 new, 18 added to, 21 trimmed, 15 sold out. Share-count changes; largest moves by dollar size first.

New positions (14)

  • ABVX$ABVXAbivax S.A.$2.3M

    first bought this quarter

  • VIR$VIRVir Biotechnology, Inc.$2.2M

    first bought this quarter

  • BIOA$BIOABioAge Labs, Inc.$1.7M

    first bought this quarter

  • NVO$NVONOVO NORDISK A S$1.2M

    first bought this quarter

  • ADAG$ADAGAdagene Inc.$1.0M

    first bought this quarter

  • DFTX$DFTXDefinium Therapeutics, Inc.$941K

    first bought this quarter

+8 more in the Excel export

Added to (18)

  • KLAC$KLACKLA CORP+798%

    now $53.8M · held 5 qtrs

  • NKTR$NKTRNEKTAR THERAPEUTICS+161%

    now $5.7M · held 4 qtrs

  • HALO$HALOHALOZYME THERAPEUTICS, INC.+229%

    now $2.6M · held 6+ qtrs

  • CORT$CORTCORCEPT THERAPEUTICS INC+21%

    now $5.0M · held 6+ qtrs

  • BIIB$BIIBBIOGEN INC.+80%

    now $1.9M · held 2 qtrs, 2 adds in a row

  • ZBIO$ZBIOZenas BioPharma, Inc.+34%

    now $2.4M · held 2 qtrs, 2 adds in a row

+12 more in the Excel export

Trimmed (21)

  • CMPS$CMPSCOMPASS Pathways plc-92%

    now $425K · held 2 qtrs

  • GPCR$GPCRStructure Therapeutics Inc.-76%

    now $1.3M · held 5 qtrs

  • OCUL$OCULOCULAR THERAPEUTIX, INC-94%

    now $203K · held 2 qtrs

  • QURE$QUREuniQure N.V.-50%

    now $2.3M · held 6+ qtrs

  • PHAT$PHATPhathom Pharmaceuticals, Inc.-72%

    now $597K · held 5 qtrs

  • NTLA$NTLAIntellia Therapeutics, Inc.-13%

    now $6.8M · held 5 qtrs

+15 more in the Excel export

Sold out (15)

  • NVCR$NVCRNovoCure Ltdwas $2.2M

    held 8+ qtrs

  • ENGN$ENGNenGene Therapeutics Inc.was $1.7M

    held 1 qtr

  • RARE$RAREUltragenyx Pharmaceutical Inc.was $1.3M

    held 6+ qtrs

  • KALV$KALVKalVista Pharmaceuticals, Inc.was $1.1M

    held 9+ qtrs

  • VSTM$VSTMVerastem, Inc.was $795K

    held 2 qtrs

  • APGE$APGEApogee Therapeutics, Inc.was $758K

+9 more in the Excel export

Firm AUM (Form ADV): $239.1M as of 2025-12-31 · SEC IAPD

Share

Holdings by quarter

Every 13F Birchview Capital, LP has filed, 32 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow Birchview Capital?

Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.

Average quality of Birchview Capital's top 20 holdings: 61/100 (our AI quality score, weighted by position size; 16 of the 20 are scored)

Top 10 since filing

-21.1%

Value-weighted move of the 10 largest stock positions

Turnover

12%

Last quarter; 44% over the last 4

Top 10 weight

60%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

79%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q1 2025 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

Birchview Capital, LP disclosed 72 positions worth $213.8M in its Form 13F-HR for Q2 2026, led by $KLAC (KLA CORP) at 25.2% of the equity portfolio, followed by $BMY and $LRCX. During the quarter the fund opened 14 new positions and exited 15 — including a new stake in $ABVX and a full exit from $NVCR. The portfolio is most concentrated in Healthcare (61.3% of disclosed assets). All figures are sourced directly from Birchview Capital, LP’s Form 13F-HR filing with the SEC under CIK 1618205.

Funds like this

managers whose biggest positions overlap Birchview Capital's
RTW INVESTMENTS, LP$11.71B 13F book · 8 shared top holdingsPTGXNBIXSTOKACADDIADEMA PARTNERS LP$791.35M 13F book · 8 shared top holdingsBMYCORTUTHRQUREVestal Point Capital, LP$4.28B 13F book · 7 shared top holdingsNBIXNKTRUTHRBMYBVF INC/IL$3.91B 13F book · 6 shared top holdingsNKTRSTOKALKSOLMASiren, L.L.C.$4.94B 13F book · 7 shared top holdingsSLDBSTOKCYTKOLMADeep Track Capital, LP$6.87B 13F book · 7 shared top holdingsALKSCLDXVERAUTHR

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: Birchview Capital, LP

13F Pro is an AI hedge fund tracker and stock research platform. For Birchview Capital, LP (SEC CIK: 1618205), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in Birchview Capital, LP's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.